Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular
Pharma
AZ nets key hypertension nod for Baxfendy, plus new Fasenra use
The FDA has given the all-clear to AZ’s baxdrostat—now christened Baxfendy—with a first-in-class approval to treat patients with high blood pressure.
Fraiser Kansteiner
May 18, 2026 11:23am
Esperion to go private in potential $1.1B buyout by ArchiMed
May 1, 2026 11:26am
UK cost watchdog clears Novo's Wegovy for cardio risk reduction
Apr 1, 2026 9:38am
Rocket is priming a limited launch of its 1st gene therapy nod
Mar 27, 2026 10:25am
Esperion pays $75M for Corstasis and FDA-approved nasal spray
Mar 3, 2026 8:40am
Stada sets sights on €85M Saudi Arabia manufacturing hub
Feb 17, 2026 2:28pm
